LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibited Notch signalling in tumor cell lines and endothelial cells (IC 50 range: 0.005-20 nM). LY900009 can be used for advanced cancer research. In Vivo LY900009 (oral gavage; 3 mg/kg; single dosage) revealed inhibition of angiogenesis through formation of leaky vasculature and produced tumour regression in Notch-dependent tumour models in a rat model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid